Genetic epilepsies and developmental and epileptic encephalopathies (DEEs) significant impact the quality of life of patients.
For children with complex needs like developmental epileptic encephalopathies (DEEs) transition to adult care can be challenging.
Up to date summary of antisense oligonucleotides (ASOs) and their role in the treatment of genetic epilepsies.
Torie Robinson’s lived experience makes her a powerful advocate for improving care for those with epilepsy.
Sleep problems are very common in children with early-life epilepsy.
In children presenting with DEEs, genetic diagnoses can be made in over 50% of cases and inform precision medicine approaches to treatment.
Using computational analysis common symptoms for 5 phenotypes of SCN2A were found. The model also predicted gain & loss of function variants.
Natural history studies are critical for clinical trial design & registration of new treatments for developmental epileptic encephalopathies.
This study showed a direct relationship between autism behaviour and SCN2A loss of function mutation in a mouse model.
This study found behaviour abnormalities in SCN2A mouse models that can be used to assess the effectiveness of new treatments.
Outstanding plenary from Greg Pratt #HGSA2022ASM discussing #inequities in health outcomes for Aboriginal and Torres Strait Islander people + how their careful consultation on country is improving #equity of access to #genomics & #culturalsafety
2It was great to be able to present @swanaus parents views around genomic data, DNA samples and consent this morning at #HGSA2022. #SWAN parents want greater control over their child’s genomic data including who has access to it and how it is used.
© All rights reserved. SCN2A Australia | Privacy Policy
